Treatment of PD-1/PD-L1 Inhibitor-Induced Dermatitis Resolves Concomitant Eruptive Keratoacanthomas

JAMA Dermatol. 2020 May 1;156(5):598-600. doi: 10.1001/jamadermatol.2020.0176.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Inflammatory Agents / administration & dosage*
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects*
  • B7-H1 Antigen / antagonists & inhibitors
  • Drug Eruptions / drug therapy
  • Drug Eruptions / etiology*
  • Female
  • Humans
  • Immunotherapy / adverse effects
  • Immunotherapy / methods
  • Keratoacanthoma / drug therapy
  • Keratoacanthoma / etiology*
  • Male
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor